# SYK Completion Checker

Last updated: 2026-07-05 | pipeline: lean-6module-v1.1 | as_of: 2026-07-05

---

## Standard File Set Checklist

| File | Status | Notes |
|---|---|---|
| raw/10k_fy2025_extract.md | DONE | Pre-existing (secondary-sourced, SEC 403 fallback) |
| raw/q1_2026_earnings_extract.md | DONE | Pre-existing (secondary-sourced, SEC 403 fallback) |
| facts.md | DONE | EVIDENCE (51 numbered items) / INTERPRETATION (9 items) / SENTIMENT (3 items) / OPEN (9 items) |
| claim_ledger.csv | DONE | 71 claims, each with source_id, tier, as_of date |
| source_register.md | DONE | 22 sources registered, >=6 minimum requirement met (A1/A2 primary or proxy: 6; B1/B2 secondary: 15; C1: 1) |
| business_model.md | DONE | Two segments (MedSurg & Neurotechnology / Orthopaedics incl. Mako) + segment-divergence flag |
| value_chain_map.md | DONE | Upstream/SYK/downstream + profit pool table + bottleneck candidates |
| moat_map.md | DONE | 4 moat sources scored + weaknesses + scorecard table |
| operator_underwriting.md | DONE | CEO Kevin Lobo graded 4/5 with explicit rationale |
| bottleneck_map.md | DONE | Mako installed-base pulls implants + China VBP/domestic-robotics-as-inverted-bottleneck (career-relevant module) |
| financials/financial_quality.md | DONE | Margin trend, cash flow quality, leverage trend, one-off registry, verdict |
| inversion_map.md | DONE | 4 kill paths with evidence-for/against + what-would-not-kill-thesis section |
| valuation.md | DONE | Peer multiple analysis + 3-scenario IRR + buy-below table |
| model/scenario_model.csv | DONE | Bear/base/bull at 3yr/5yr with full methodology notes |
| ic_panel.md | DONE | 5-soul initial verdicts + 1 critique round + chair synthesis + kill criteria — unanimous STARTER, no fabricated quotes |
| decision_card.json | DONE | Full schema matching GEV/GEHC/MSFT exemplar structure |
| decision_card.md | DONE | Human-readable summary with career note section |
| brief-v1.html | DONE | SYK 决策简报 as_of 2026-07-05, MSFT/GEHC template adapted, renders correctly (confirmed via Launch preview) |
| audit.md | DONE | Stale-claim check, internal consistency (14 checks, all PASS), one-off registry, source coverage, robustness-rule compliance |
| completion_checker.md | DONE (this file) | |
| research_status.md | DONE | |
| freshness.json | DONE | |

---

## Completeness Self-Assessment: ~65-70% (DECISION_DRAFT)

**What's strong**:
- Price independently verified against 2 sources, exact match to frozen input ($326.54)
- Mako installed-base and procedure-volume metrics (3,000+ systems, 1M+/2M+ procedures) are genuine, IR-disclosed, multi-period-consistent facts — a stronger evidentiary base than a pure analyst narrative
- FY2025 full-year detail plus Q1 2026 (most recent quarter) both captured with segment-level detail
- Cyber incident (facts.md E21) is a single, dated, well-quantified event with a clear before/after timeline (occurrence, shutdown duration, restoration date, financial impact) — genuinely well-documented despite being a disruptive event
- 3-scenario IRR model built with explicit, documented assumptions and a clean methodology note, directly comparable to the GEV/GEHC exemplar structure
- 5-soul IC panel completed with genuine critique-round dynamics (not just 5 independent paragraphs) and zero fabricated quotes
- CEO incentive alignment (93% at-risk compensation) is a CONFIRMED figure, closing a gap that was left unresolved in the GEHC comparison

**What's explicitly incomplete** (see facts.md OPEN O1-O9 for full detail):
- O1: Direct SEC 10-K/10-Q text never read (403 blocked, per-rule no retry) — relied on official IR press releases + A2-proxy structured mirrors, cross-checked but not primary-verbatim
- O2: Orthopaedics segment reported-vs-organic growth divergence (+4.3% vs +9.5%) unresolved — the single most important segment-level data-quality question
- O3: China-specific revenue percentage/dollar figure and robotics-competitive-impact data not found — the single most important STRATEGIC gap, directly analogous to (but thinner-disclosed than) GEHC's China question
- O4: Implant "pull-through" economics (attach rate, ASP premium) completely unquantified — the single most important MOAT-QUANTIFICATION gap, analogous to GEHC's AI-monetization gap
- O6: H2 2026 recapture of the $375M deferred cyber-incident sales cannot yet be confirmed — the single most important NEAR-TERM validation point
- O8: No earnings call transcript fetched this run (time/efficiency tradeoff, consistent with DECISION_DRAFT-not-perfection target)

**Ceiling determination**: This dossier is capped at DECISION_DRAFT, not COMPLETE, primarily due to O2/O3/O4/O6/O8. This is consistent with the target completeness band ("DECISION_DRAFT ~65-70% is the target, not perfection") — the checker confirms the run hit its target completeness band without over- or under-shooting.

---

## Verdict

**PASS — dossier meets the DECISION_DRAFT standard.** All required files present, internally consistent (per audit.md), with explicit, honest OPEN-item registration rather than false completeness. Recommended next-refresh priorities, in order: (1) Q2 2026 earnings (expected ~late July 2026) — resolves O6 (cyber recapture) and provides a fresh read on organic growth re-acceleration; (2) any China-specific revenue/robotics-competitive data point (resolves O3, the single highest career-relevance gap); (3) any company disclosure or credible channel-check quantifying implant pull-through (resolves O4); (4) direct 10-K MD&A/footnote read if SEC access improves (resolves O1, clarifies O2's segment divergence).
